Figure: Current status of the Tofersen hardship case program on 03/01/2023 with participants from the ID-ALS study.
Tofersen therapy is appropriate for patients who have a mutation in the SOD1 gene. Transfer to the hardship program is a direct benefit for participants in the ID-ALS study.
We would like to thank all the people who have participated in our genetic study so far and provided their data for research. The research project could only succeed through their support. The study is a good example of successful collaboration between specialized ALS centers, outpatient partners and an industry partnership with the Biogen company.
For more information about the purpose of the study, the process, the time involved, and the options for reporting results, see: https://www.ambulanzpartner.de/studie-id-als/
Thank you for your interest in this project.
Your APST Team